Limits to potent antiretroviral therapy

Reviews in Medical Virology

Volumn 10, Issue 6, 2000, Pages 385-393

  Telenti, Amalio ^a   Rizzardi, G Paolo ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; INTERLEUKIN 2; NEVIRAPINE; OKT 3; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; DYSLIPIDEMIA; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; REVIEW; T LYMPHOCYTE; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0033665980     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1654(200011/12)10:6<385::AID-RMV296>3.0.CO;2-1     Document Type: Review

References (63)

1. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
2. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
3. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
4. Can HIV be eradicated?
5. How immune-based interventions can change HIV therapy
6. The immunopathogenesis of HIV-1 infection
7. HIV treatment failure: Testing for HIV resistance in clinical practice
8. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
9. Toward HIV eradication or remission: The tasks ahead
10. Viral dynamics in human immunodeficiency virus type 1 infection
11. Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
12. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
13. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
14. Viral dynamics in HIV-1 infection
15. Latent reservoirs of HIV: Obstacles to the eradication of virus
16. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
17. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
18. Strategies for immune restoration
19. Therapeutic perspectives in HIV-1 infection from recent advances in HIV-1 pathogenesis: It is time to move on
20. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
21. Re-emergence of HIV after stopping therapy
22. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
23. Effect of mycophenolic acid on HIV infection in vitro and in vivo
24. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
25. The moving target: Mechanisms of HIV persistence during primary infection
26. + T cell counts
27. Changes in thymic function with age and during the treatment of HIV infection
28. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
29. Review of 'Experimental infection of monkeys with Langat virus II. Turnover of circulating virus' by Nathanson N and Harrington B
30. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
31. Incidence and impact of resistance against approved antiretroviral drugs
32. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
33. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
34. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
35. HIV-1 drug resistance in newly infected individuals
36. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
37. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
38. Transmission of antiretroviral-drug-resistant HIV-1 variants
39. Sexual transmission of an HIV-1 variant resistant to multipie reverse-transcriptase and protease inhibitors
40. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
41. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
42. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
43. Heterogeneity of response to antiretroviral therapy
44. Virological and immunological characteristics of HIV treatment failure
45. Novel compounds in preclinical/early clinical development
46. Pharmacogenomics: Translating functional genomics into rational therapeutics
47. Pharmacogenetics and future drug development and delivery
48. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
49. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
50. HIV and AIDS. Gap between biology and reality in AIDS
51. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
52. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
53. A syndrome of lipoatrophy., lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
54. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
55. Viral load and heterosexual transmission of human immunodeficiency virus type 1
56. Drug-resistance genotyping in HIV-1 therapy: The VIR-ADAPT randomised controlled trial
57. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
58. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
59. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
60. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
61. Population level protection attributable to host genetic markers conferring resistance to AIDS progression
62. Human genetic factors that impact HIV infection and progression
63. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1